• Vaccine Name: Dengvaxia
• Target Pathogen: Dengue Virus
• Target Disease: Dengue Fever
• Product Name: Dengvaxia®
• Manufacturer: Sanofi Pasteur
• Type: Recombinant vector vaccine
• Status: Licensed
• Location Licensed: immunization implementation has been limited to subnational public health programs in Brazil and the Philippines
• Host Species for Licensed Use: Human
• prM from Dengue virus 1 gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• prM from Dengue virus 2 gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• prM from Dengue virus 3 gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• prM from Dengue virus 4 gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• E from Dengue virus 1 gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• E protein from Dengue Virus 2 gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• E from Dengue virus 3 gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• E from Dengue virus 4 gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• POLY gene engineering:
  • Type: Recombinant vector construction
  • Description: Dengvaxia® is a live attenuated tetravalent vaccine consisting of chimeras made up of structural pre-membrane (prM) and envelope (E) genes of the four DENV types combined with the nonstructural genes of yellow fever 17D vaccine strain. (Thomas and Yoon, 2019)
  • Detailed Gene Information: Click Here.
• Preservative: none
• Immunization Route: Intramuscular injection (i.m.)
• Approved Age for Licensed Use: (Thomas and Yoon, 2019) Only people with evidence of a past dengue infection should be vaccinated based on an antibody test, or on a documented laboratory confirmed dengue infection in the past. The vaccine should be used within the indicated age range, which in most countries is 9–45 years. The age group to target for vaccination depends on the dengue transmission intensity in a given country;
• Description: Dengvaxia® is a live attenuated tetravalent vaccine consisting of chimeras made up of structural pre-membrane (prM) and envelope (E) genes of the four DENV types combined with the nonstructural genes of yellow fever 17D vaccine strain (chimeric yellow fever dengue – CYD) (Thomas and Yoon, 2019)

Human Response

• Vaccination Protocol: Healthy children between the ages of 9 and 16 years received three injections of recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) or placebo at months 0, 6, and 12 under blinded conditions. (Villar et al., 2015)
• Immune Response: All groups were compared to the control group, Statistically significant difference in antibodies for all serotypes for month 7 and month 13 after injection was investigated. The results showed no statistically significant difference in antibodies for all serotypes at baseline (Villar et al., 2015).
• Side Effects: Four serious adverse events were deemed to be vaccine-related by investigators and sponsors: three in the vaccine group (a moderate asthma attack 16 hours after the first injection, allergic urticaria 4 hours after the second injection, and acute peripheral polyneuropathy associated with viral meningitis 3 days after the first injection, without detectable vaccine virus in samples, unspecified seizures 18 hours after the first injection, without detectable vaccine virus in samples,). All children recovered fully without sequelae. (Villar et al., 2015)
• Efficacy: Vaccine Efficacy for 176 cases of virologically confirmed dengue in the vaccine group and 221 in the control group that were diagnosed more than 28 days after the third dose (primary outcome): Serotype 1: 50.3%, Serotype 2: 42.3% , Serotype 3: 74.0%, Serotype 4: 77.7%. Vaccine Efficacy for all children who received at least one injection from month 0 to month 25: Serotype 1: 54.8%, Serotype 2: 50.2%, Serotype 3: 74.2%, Serotype 4: 80.9% (Villar et al., 2015).